2012: News in neurology;Neurologie

Revue Medicale Suisse

Volumn 9, Issue 368, 2013, Pages 62-65

  Alvarez, V ^a   Rossetti, A O ^a   Michel, P ^a   Kuntzer, T ^a   Nater, B ^a   Demonet J F ^a   Schluep, M ^a   Du Pasquier, R ^a   Vingerhoets, F ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIOXIDANT; LORAZEPAM; METHYLPHENIDATE; MIDAZOLAM; PERAMPANEL;

ALZHEIMER DISEASE; ARTICLE; CEREBROVASCULAR ACCIDENT; DRUG EFFECT; DRUG EFFICACY; EPILEPTIC STATE; HEART ATRIUM FIBRILLATION; HEART WORK; MIGRAINE; MULTIPLE SCLEROSIS; MYOPATHY; NEUROLOGY; PARKINSON DISEASE; TAI CHI;

ANTICONVULSANTS; CEREBROVASCULAR DISORDERS; DEMENTIA; DYSKINESIAS; EPILEPSY; HUMANS; MENTAL DISORDERS; NEUROIMMUNOMODULATION; NEUROLOGY; NEUROMUSCULAR DISEASES; THERAPIES, INVESTIGATIONAL;

EID: 84872713798     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Meador KJ, Baker GA, Browning N, Bromley RL. Effects of fetal antiepileptic drug exposure. Neurology 2012;78:1207-14.
2. ** Hernández-Díaz S, Smith CR, Shen A, et al. Comparative safety of antiepileptic drugs during pregnancy. Neurology 2012;78:1692-9.
3. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15.
4. Geithner J, Schneider F, Berneiser J, et al. Predictors for long-term seizure outcome in juvenile myoclonic epilepsy: 25-63 years of follow-up. Epilepsia 2012;53:1379-86.
5. ** Silbergleit R, Durkalski V, Lowenstein D, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med 2012;366:591-600.
6. ** Diener H, Connolly SJ, Ezekowitz MD, et al. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurol 2010;9:1157-63.
7. ** Hankey GJ, Patel MR, Stevens SR, et al. Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: A subgroup analysis of ROCKET AF. Lancet Neurol 2012;11:315-22.
8. Lawrence M, Kerr S, Mcvey C, Godwin J. The effectiveness of secondary prevention lifestyle interventions designed to change lifestyle behavior following stroke: Summary of a systematic review. Int J Stroke 2012;7:243-7.
9. The IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): A randomised controlled trial. Lancet 2012;379:2352-63.
10. Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med 2012;366:1099-107.
11. * Zinkstok SM, Roos YB, Investigators on behalf of the A. Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: A randomised controlled trial. Lancet 2012;380:731-7.
12. Nogueira RG, Lutsep HL, Gupta R, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): A randomised trial. Lancet 2012; http://dx.doi.org/10.1016/ S0140-6736(12)61299-9
13. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): A randomised, parallel-group, non-inferiority trial. Lancet 2012; http://dx.doi.org/10.1016/S0140-6736(12)61384-1
14. Lansberg MG, Straka M, Kemp S, et al. MRI profile and response to endovascular reperfusion after stroke (DEFUSE 2): A prospective cohort study. Lancet Neurol 2012;11:860-7.
15. * Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: A multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-96.
16. ** Eckstrom E, Stock R, Galver J, Maddalozzo G, Batya SS. Tai Chi and postural stability in patients with Parkinson's disease. N Engl J Med 2012;366:511-9.
17. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology 2012;78:1229-36.
18. Miyasaki JM, Long J, Mancini D, et al. Palliative care for advanced Parkinson disease: An interdisciplinary clinic and new scale, the ESAS-PD. Parkinsonism Relat Disord 2012; epub ahead of print.
19. Wals PD, Deceuninck G, Toth E, et al. Risk of Guillain-Barré syndrome following H1N1 influenza vaccination in Quebec. JAMA 2012;308:175-81.
20. Nobile-Orazio E, Cocito D, Jann S, et al. Intravenous immunoglobulin versus intravenous methylprednisolone for chronic inflammatory demyelinating polyradiculoneuropathy: A randomised controlled trial. Lancet Neurol 2012;11:493-502.
21. * Wahbi K, Meune C, Porcher R, et al. Electrophysiological study with prophylactic pacing and survival in adults with myotonic dystrophy and conduction system disease. JAMA 2012;307:1292-301.
22. Wahbi K, Béhin A, Charron P, et al. High cardiovascular morbidity and mortality in myofibrillar myopathies due to DES gene mutations: A 10-year longitudinal study. Neuromuscul Disord 2012;22:211-8.
23. * Diaz-Manera J, Martinez-Hernandez E, Querol L, et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 2012;78:189-93.
24. Färkkilä M, Diener H, Géraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT 1F receptor agonist, for the acute treatment of migraine: A phase 2 randomised, placebo-controlled, parallel-group, dose-ranging study. Lancet Neurol 2012;11:405-13.
25. * Silberstein SD, Dodick DW, Lindblad AS, et al. Randomized, placebo-controlled trial of propranolol added to topiramate in chronic migraine. Neurology 2012;78:976-84.
26. Jackson JL, Kuriyama A, Hayashino Y. Botulinum toxin A for prophylactic treatment of migraine and tension headaches in adults. A meta-analysis. JAMA 2012;307:1736-45.
27. Galasko DR, Peskind E, Clark CM, et al. Antioxidants for Alzheimer disease. A randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 2012;69:836-41.
28. Howard R, McShane R, Lindesay J, et al. Donepezil and Memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 2012;366:893-903.
29. * Mori E, Ikeda M, Kosaka K, Investigators on behalf of the D-DS. Donepezil for dementia with Lewy bodies: A randomized, placebo-controlled trial. Ann Neurol 2012;72:41-52.
30. Pariente A, Fourrier-Réglat A, Ducruet T, et al. Antipsychotic use and myocardial infarction in older patients with treated dementia. Arch Intern Med 2012;172:648-53.
31. * Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107.
32. * Havrdova E, Kita M, Yang M, et al. Placebo-controlled phase 3 study of oral BG-12 or Glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
33. Comi G, Kappos L, Olsson TP, et al. Randomized trial of oral Teriflunomide for relapsing multiple sclerosis. N Engl J Med 2012;365:1293-303.
34. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 clinical trial. Neurology 2012;78:1069-78.
35. Srivastava R, Aslam M, Kalluri SR, et al. Potassium channel KIR4.1 as an immune target in multiple sclerosis. N Engl J Med 2012;367:115-23.
36. Tradtrantip L, Zhang H, Saadoun S, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol 2012;71:314-22.